SLAS
SLAS is a global, non-profit professional community made up of scientists from academia, government and industry who are collectively focused on leveraging the power of technology to achieve scientific objectives.
SLAS is a global, non-profit professional community made up of scientists from academia, government and industry who are collectively focused on leveraging the power of technology to achieve scientific objectives.
We are sponsors at this event!
Come and meet our team at booth #851 to discuss how bit.bio offers partnering opportunities that affords access to the most relevant parental human cell types and corresponding disease models. These models are physiologically relevant and highly characterised, offering predictive, in vitro, human cells for early drug discovery, phenotypic screening, high-content imaging applications and cell therapies.
Posters by bit.bio
- Driving experimental reproducibility and lot-to-lot biological consistency at scale in human iPSC-derived cells enabled by opti-ox technology
- Harnessing CRISPR-Ready ioGlutamatergic Neurons and ioMicroglia as functional genomics tools for drug discovery
- Physiologically relevant media unmasks severe mitochondrial dysfunction in a deterministically programmed iPSC-derived model of Huntington’s disease
- A toolbox of human iPSC-derived microglia in different genetic backgrounds and disease models for neurodegeneration drug discovery
- A scalable and well defined human CNS co-culture platform, suitable for studying excitatory/inhibitory neuron imbalances and the discovery of drugs to treat associated diseases
Posters featuring ioCells
- Drug repurposing approach to identify novel treatments for PEX10-mediated Peroxisome Biogenesis Disorder
- Integrated Strategy for Automating Method Development of Bioanalytical Ligand Binding Assays using Digital and Physical Platforms
Exhibitor Tutorial
Challenges, solutions, and progress in applying human iPSC-derived cells to drug discovery
Tuesday, January 28, 2025
8:30 AM - 10:00 AM
Room/Location: 24B
Synopsis:
In drug discovery, researchers need reliable, ready-to-use human cell models that deliver reproducible results at every stage of the workflow. Join four industry experts as they present data on bit.bio’s deterministically programmed human iPSC-derived ioCells used across key drug discovery stages. Through case studies and real-world applications, you will learn how these cells and the associated protocols support workflows in target identification, assay development, disease modelling, and toxicology.
Key learning points:
- Discover quick and easy generation of gene knockouts and CRISPR screens for target ID and validation in human iPSC-derived neurons and microglia using CRISPR-Ready ioCells
- Learn about assay development in neuroinflammation and demyelinating diseases using neuronal and glial co-cultures
- Explore disease modelling in excitatory neurons with ALS-associated phenotypes using high-throughput MEA
- See data for predicting drug-induced liver injury in toxicology studies with new human iPSC-derived liver models
Attendees will leave the session with knowledge of new solutions to generate human-relevant data in vitro to accelerate drug development.
Speakers:
- Tim Smith, PhD, bit.bio, Associate Director of Sales
- Malika Bsibsi, PhD, Charles River Laboratories, Research Leader Neurosciences
- Austin Passaro, PhD, Axion BioSystems, Global Product Manager MEA Systems
- Cicely Schramm, PhD, Sartorius, Head of Biology, Cell Imaging